By Colin Kellaher
Johnson & Johnson's Janssen Pharmaceutical Cos. unit on Wednesday said the U.S. Food and Drug Administration approved a six-month version of its antipsychotic Invega.
The drug maker said Invega Hafyera is the first FDA-approved twice-yearly injectable for the treatment of schizophrenia in adults.
Janssen said patients must first be treated with its Invega Sustenna one-month drug for at least four months or its Invega Trinza three-month dose at least once before switching to the new six-month Invega Hafyera.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
09-01-21 0845ET